Cargando…
Prognostic gene expression signature for high-grade serous ovarian cancer
BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ~4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic sig...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484370/ https://www.ncbi.nlm.nih.gov/pubmed/32473302 http://dx.doi.org/10.1016/j.annonc.2020.05.019 |
| _version_ | 1783580981263859712 |
|---|---|
| author | Millstein, J. Budden, T. Goode, E. L. Anglesio, M. S. Talhouk, A. Intermaggio, M. P. Leong, H. S. Chen, S. Elatre, W. Gilks, B. Nazeran, T. Volchek, M. Bentley, R. C. Wang, C. Chiu, D. S. Kommoss, S. Leung, S. C. Y. Senz, J. Lum, A. Chow, V. Sudderuddin, H. Mackenzie, R. George, J. Fereday, S. Hendley, J. Traficante, N. Steed, H. Koziak, J. M. Köbel, M. McNeish, I. A. Goranova, T. Ennis, D. Macintyre, G. Silva De Silva, D. Ramón y Cajal, T. García-Donas, J. Hernando Polo, S. Rodriguez, G. C. Cushing-Haugen, K. L. Harris, H. R. Greene, C. S. Zelaya, R. A. Behrens, S. Fortner, R. T. Sinn, P. Herpel, E. Lester, J. Lubiński, J. Oszurek, O. Tołoczko, A. Cybulski, C. Menkiszak, J. Pearce, C. L. Pike, M. C. Tseng, C. Alsop, J. Rhenius, V. Song, H. Jimenez-Linan, M. Piskorz, A. M. Gentry-Maharaj, A. Karpinskyj, C. Widschwendter, M. Singh, N. Kennedy, C. J. Sharma, R. Harnett, P. R. Gao, B. Johnatty, S. E. Sayer, R. Boros, J. Winham, S. J. Keeney, G. L. Kaufmann, S. H. Larson, M. C. Luk, H. Hernandez, B. Y. Thompson, P. J. Wilkens, L. R. Carney, M. E. Trabert, B. Lissowska, J. Brinton, L. Sherman, M. E. Bodelon, C. Hinsley, S. Lewsley, L. A. Glasspool, R. Banerjee, S. N. Stronach, E. A. Haluska, P. Ray-Coquard, I. Mahner, S. Winterhoff, B. Slamon, D. Levine, D. A. Kelemen, L. E. Benitez, J. Chang-Claude, J. Gronwald, J. Wu, A. H. Menon, U. Goodman, M. T. Schildkraut, J. M. Wentzensen, N. Brown, R. Berchuck, A. Chenevix-Trench, G. deFazio, A. Gayther, S. A. García, M. J. Henderson, M. J. Rossing, M. A. Beeghly-Fadiel, A. Fasching, P. A. Orsulic, S. Karlan, B. Y. Konecny, G. E. Huntsman, D. G. Bowtell, D. D. Brenton, J. D. Doherty, J. A. Pharoah, P. D. P. Ramus, S. J. |
| author_facet | Millstein, J. Budden, T. Goode, E. L. Anglesio, M. S. Talhouk, A. Intermaggio, M. P. Leong, H. S. Chen, S. Elatre, W. Gilks, B. Nazeran, T. Volchek, M. Bentley, R. C. Wang, C. Chiu, D. S. Kommoss, S. Leung, S. C. Y. Senz, J. Lum, A. Chow, V. Sudderuddin, H. Mackenzie, R. George, J. Fereday, S. Hendley, J. Traficante, N. Steed, H. Koziak, J. M. Köbel, M. McNeish, I. A. Goranova, T. Ennis, D. Macintyre, G. Silva De Silva, D. Ramón y Cajal, T. García-Donas, J. Hernando Polo, S. Rodriguez, G. C. Cushing-Haugen, K. L. Harris, H. R. Greene, C. S. Zelaya, R. A. Behrens, S. Fortner, R. T. Sinn, P. Herpel, E. Lester, J. Lubiński, J. Oszurek, O. Tołoczko, A. Cybulski, C. Menkiszak, J. Pearce, C. L. Pike, M. C. Tseng, C. Alsop, J. Rhenius, V. Song, H. Jimenez-Linan, M. Piskorz, A. M. Gentry-Maharaj, A. Karpinskyj, C. Widschwendter, M. Singh, N. Kennedy, C. J. Sharma, R. Harnett, P. R. Gao, B. Johnatty, S. E. Sayer, R. Boros, J. Winham, S. J. Keeney, G. L. Kaufmann, S. H. Larson, M. C. Luk, H. Hernandez, B. Y. Thompson, P. J. Wilkens, L. R. Carney, M. E. Trabert, B. Lissowska, J. Brinton, L. Sherman, M. E. Bodelon, C. Hinsley, S. Lewsley, L. A. Glasspool, R. Banerjee, S. N. Stronach, E. A. Haluska, P. Ray-Coquard, I. Mahner, S. Winterhoff, B. Slamon, D. Levine, D. A. Kelemen, L. E. Benitez, J. Chang-Claude, J. Gronwald, J. Wu, A. H. Menon, U. Goodman, M. T. Schildkraut, J. M. Wentzensen, N. Brown, R. Berchuck, A. Chenevix-Trench, G. deFazio, A. Gayther, S. A. García, M. J. Henderson, M. J. Rossing, M. A. Beeghly-Fadiel, A. Fasching, P. A. Orsulic, S. Karlan, B. Y. Konecny, G. E. Huntsman, D. G. Bowtell, D. D. Brenton, J. D. Doherty, J. A. Pharoah, P. D. P. Ramus, S. J. |
| author_sort | Millstein, J. |
| collection | PubMed |
| description | BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ~4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic signature for OS in patients with HGSOC. PATIENTS AND METHODS: Expression of 513 genes, selected from a meta-analysis of 1455 tumours and other candidates, was measured using NanoString technology from formalin-fixed paraffin-embedded tumour tissue collected from 3769 women with HGSOC from multiple studies. Elastic net regularization for survival analysis was applied to develop a prognostic model for 5-year OS, trained on 2702 tumours from 15 studies and evaluated on an independent set of 1067 tumours from six studies. RESULTS: Expression levels of 276 genes were associated with OS (false discovery rate < 0.05) in covariate-adjusted single-gene analyses. The top five genes were TAP1, ZFHX4, CXCL9, FBN1 and PTGER3 (P < 0.001). The best performing prognostic signature included 101 genes enriched in pathways with treatment implications. Each gain of one standard deviation in the gene expression score conferred a greater than twofold increase in risk of death [hazard ratio (HR) 2.35, 95% confidence interval (CI) 2.02–2.71; P < 0.001]. Median survival [HR (95% CI)] by gene expression score quintile was 9.5 (8.3 to –), 5.4 (4.6–7.0), 3.8 (3.3–4.6), 3.2 (2.9–3.7) and 2.3 (2.1–2.6) years. CONCLUSION: The OTTA-SPOT (Ovarian Tumor Tissue Analysis consortium - Stratified Prognosis of Ovarian Tumours) gene expression signature may improve risk stratification in clinical trials by identifying patients who are least likely to achieve 5-year survival. The identified novel genes associated with the outcome may also yield opportunities for the development of targeted therapeutic approaches. |
| format | Online Article Text |
| id | pubmed-7484370 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74843702020-09-11 Prognostic gene expression signature for high-grade serous ovarian cancer Millstein, J. Budden, T. Goode, E. L. Anglesio, M. S. Talhouk, A. Intermaggio, M. P. Leong, H. S. Chen, S. Elatre, W. Gilks, B. Nazeran, T. Volchek, M. Bentley, R. C. Wang, C. Chiu, D. S. Kommoss, S. Leung, S. C. Y. Senz, J. Lum, A. Chow, V. Sudderuddin, H. Mackenzie, R. George, J. Fereday, S. Hendley, J. Traficante, N. Steed, H. Koziak, J. M. Köbel, M. McNeish, I. A. Goranova, T. Ennis, D. Macintyre, G. Silva De Silva, D. Ramón y Cajal, T. García-Donas, J. Hernando Polo, S. Rodriguez, G. C. Cushing-Haugen, K. L. Harris, H. R. Greene, C. S. Zelaya, R. A. Behrens, S. Fortner, R. T. Sinn, P. Herpel, E. Lester, J. Lubiński, J. Oszurek, O. Tołoczko, A. Cybulski, C. Menkiszak, J. Pearce, C. L. Pike, M. C. Tseng, C. Alsop, J. Rhenius, V. Song, H. Jimenez-Linan, M. Piskorz, A. M. Gentry-Maharaj, A. Karpinskyj, C. Widschwendter, M. Singh, N. Kennedy, C. J. Sharma, R. Harnett, P. R. Gao, B. Johnatty, S. E. Sayer, R. Boros, J. Winham, S. J. Keeney, G. L. Kaufmann, S. H. Larson, M. C. Luk, H. Hernandez, B. Y. Thompson, P. J. Wilkens, L. R. Carney, M. E. Trabert, B. Lissowska, J. Brinton, L. Sherman, M. E. Bodelon, C. Hinsley, S. Lewsley, L. A. Glasspool, R. Banerjee, S. N. Stronach, E. A. Haluska, P. Ray-Coquard, I. Mahner, S. Winterhoff, B. Slamon, D. Levine, D. A. Kelemen, L. E. Benitez, J. Chang-Claude, J. Gronwald, J. Wu, A. H. Menon, U. Goodman, M. T. Schildkraut, J. M. Wentzensen, N. Brown, R. Berchuck, A. Chenevix-Trench, G. deFazio, A. Gayther, S. A. García, M. J. Henderson, M. J. Rossing, M. A. Beeghly-Fadiel, A. Fasching, P. A. Orsulic, S. Karlan, B. Y. Konecny, G. E. Huntsman, D. G. Bowtell, D. D. Brenton, J. D. Doherty, J. A. Pharoah, P. D. P. Ramus, S. J. Ann Oncol Article BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ~4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic signature for OS in patients with HGSOC. PATIENTS AND METHODS: Expression of 513 genes, selected from a meta-analysis of 1455 tumours and other candidates, was measured using NanoString technology from formalin-fixed paraffin-embedded tumour tissue collected from 3769 women with HGSOC from multiple studies. Elastic net regularization for survival analysis was applied to develop a prognostic model for 5-year OS, trained on 2702 tumours from 15 studies and evaluated on an independent set of 1067 tumours from six studies. RESULTS: Expression levels of 276 genes were associated with OS (false discovery rate < 0.05) in covariate-adjusted single-gene analyses. The top five genes were TAP1, ZFHX4, CXCL9, FBN1 and PTGER3 (P < 0.001). The best performing prognostic signature included 101 genes enriched in pathways with treatment implications. Each gain of one standard deviation in the gene expression score conferred a greater than twofold increase in risk of death [hazard ratio (HR) 2.35, 95% confidence interval (CI) 2.02–2.71; P < 0.001]. Median survival [HR (95% CI)] by gene expression score quintile was 9.5 (8.3 to –), 5.4 (4.6–7.0), 3.8 (3.3–4.6), 3.2 (2.9–3.7) and 2.3 (2.1–2.6) years. CONCLUSION: The OTTA-SPOT (Ovarian Tumor Tissue Analysis consortium - Stratified Prognosis of Ovarian Tumours) gene expression signature may improve risk stratification in clinical trials by identifying patients who are least likely to achieve 5-year survival. The identified novel genes associated with the outcome may also yield opportunities for the development of targeted therapeutic approaches. 2020-05-28 2020-09 /pmc/articles/PMC7484370/ /pubmed/32473302 http://dx.doi.org/10.1016/j.annonc.2020.05.019 Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license. |
| spellingShingle | Article Millstein, J. Budden, T. Goode, E. L. Anglesio, M. S. Talhouk, A. Intermaggio, M. P. Leong, H. S. Chen, S. Elatre, W. Gilks, B. Nazeran, T. Volchek, M. Bentley, R. C. Wang, C. Chiu, D. S. Kommoss, S. Leung, S. C. Y. Senz, J. Lum, A. Chow, V. Sudderuddin, H. Mackenzie, R. George, J. Fereday, S. Hendley, J. Traficante, N. Steed, H. Koziak, J. M. Köbel, M. McNeish, I. A. Goranova, T. Ennis, D. Macintyre, G. Silva De Silva, D. Ramón y Cajal, T. García-Donas, J. Hernando Polo, S. Rodriguez, G. C. Cushing-Haugen, K. L. Harris, H. R. Greene, C. S. Zelaya, R. A. Behrens, S. Fortner, R. T. Sinn, P. Herpel, E. Lester, J. Lubiński, J. Oszurek, O. Tołoczko, A. Cybulski, C. Menkiszak, J. Pearce, C. L. Pike, M. C. Tseng, C. Alsop, J. Rhenius, V. Song, H. Jimenez-Linan, M. Piskorz, A. M. Gentry-Maharaj, A. Karpinskyj, C. Widschwendter, M. Singh, N. Kennedy, C. J. Sharma, R. Harnett, P. R. Gao, B. Johnatty, S. E. Sayer, R. Boros, J. Winham, S. J. Keeney, G. L. Kaufmann, S. H. Larson, M. C. Luk, H. Hernandez, B. Y. Thompson, P. J. Wilkens, L. R. Carney, M. E. Trabert, B. Lissowska, J. Brinton, L. Sherman, M. E. Bodelon, C. Hinsley, S. Lewsley, L. A. Glasspool, R. Banerjee, S. N. Stronach, E. A. Haluska, P. Ray-Coquard, I. Mahner, S. Winterhoff, B. Slamon, D. Levine, D. A. Kelemen, L. E. Benitez, J. Chang-Claude, J. Gronwald, J. Wu, A. H. Menon, U. Goodman, M. T. Schildkraut, J. M. Wentzensen, N. Brown, R. Berchuck, A. Chenevix-Trench, G. deFazio, A. Gayther, S. A. García, M. J. Henderson, M. J. Rossing, M. A. Beeghly-Fadiel, A. Fasching, P. A. Orsulic, S. Karlan, B. Y. Konecny, G. E. Huntsman, D. G. Bowtell, D. D. Brenton, J. D. Doherty, J. A. Pharoah, P. D. P. Ramus, S. J. Prognostic gene expression signature for high-grade serous ovarian cancer |
| title | Prognostic gene expression signature for high-grade serous ovarian cancer |
| title_full | Prognostic gene expression signature for high-grade serous ovarian cancer |
| title_fullStr | Prognostic gene expression signature for high-grade serous ovarian cancer |
| title_full_unstemmed | Prognostic gene expression signature for high-grade serous ovarian cancer |
| title_short | Prognostic gene expression signature for high-grade serous ovarian cancer |
| title_sort | prognostic gene expression signature for high-grade serous ovarian cancer |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484370/ https://www.ncbi.nlm.nih.gov/pubmed/32473302 http://dx.doi.org/10.1016/j.annonc.2020.05.019 |
| work_keys_str_mv | AT millsteinj prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT buddent prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT goodeel prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT anglesioms prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT talhouka prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT intermaggiomp prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT leonghs prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT chens prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT elatrew prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT gilksb prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT nazerant prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT volchekm prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT bentleyrc prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT wangc prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT chiuds prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT kommosss prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT leungscy prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT senzj prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT luma prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT chowv prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT sudderuddinh prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT mackenzier prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT georgej prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT feredays prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT hendleyj prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT traficanten prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT steedh prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT koziakjm prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT kobelm prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT mcneishia prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT goranovat prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT ennisd prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT macintyreg prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT silvadesilvad prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT ramonycajalt prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT garciadonasj prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT hernandopolos prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT rodriguezgc prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT cushinghaugenkl prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT harrishr prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT greenecs prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT zelayara prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT behrenss prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT fortnerrt prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT sinnp prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT herpele prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT lesterj prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT lubinskij prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT oszureko prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT tołoczkoa prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT cybulskic prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT menkiszakj prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT pearcecl prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT pikemc prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT tsengc prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT alsopj prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT rheniusv prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT songh prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT jimenezlinanm prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT piskorzam prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT gentrymaharaja prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT karpinskyjc prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT widschwendterm prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT singhn prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT kennedycj prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT sharmar prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT harnettpr prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT gaob prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT johnattyse prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT sayerr prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT borosj prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT winhamsj prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT keeneygl prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT kaufmannsh prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT larsonmc prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT lukh prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT hernandezby prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT thompsonpj prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT wilkenslr prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT carneyme prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT trabertb prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT lissowskaj prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT brintonl prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT shermanme prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT bodelonc prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT hinsleys prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT lewsleyla prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT glasspoolr prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT banerjeesn prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT stronachea prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT haluskap prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT raycoquardi prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT mahners prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT winterhoffb prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT slamond prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT levineda prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT kelemenle prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT benitezj prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT changclaudej prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT gronwaldj prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT wuah prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT menonu prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT goodmanmt prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT schildkrautjm prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT wentzensenn prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT brownr prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT berchucka prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT chenevixtrenchg prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT defazioa prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT gaythersa prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT garciamj prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT hendersonmj prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT rossingma prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT beeghlyfadiela prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT faschingpa prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT orsulics prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT karlanby prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT konecnyge prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT huntsmandg prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT bowtelldd prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT brentonjd prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT dohertyja prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT pharoahpdp prognosticgeneexpressionsignatureforhighgradeserousovariancancer AT ramussj prognosticgeneexpressionsignatureforhighgradeserousovariancancer |